U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07227909) titled 'NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy' on Nov. 12.
Brief Summary: To learn if psilocybin can help to prevent or decrease the severity of chemotherapy-induced peripheral neuropathy (CIPN) in patients who are receiving chemotherapy for the treatment of breast, colorectal, and In this study, psilocybin is being compared to standard supportive care and to a placebo.
Study Start Date: May 04, 2026
Study Type: INTERVENTIONAL
Condition:
Psilocybin
Neuropathy
Intervention:
DRUG: Psilocybin (drug)
Given by po 25 mg
DRUG: Psilocybin (drug)
Given by po 1mg
OTHER: Standard of Care (SOC)
No drug
Recruit...